According to the Zhitong Finance App, Yiming Onko-B (01541.HK) issued an announcement regarding the capital increase of 50 million yuan for its subsidiary Yiming Kale Biomedical Technology (Shanghai). As of the date of this announcement, the capital increase and related industrial and commercial registration procedures have been completed. Investors have paid RMB 50 million in consideration in accordance with the capital increase agreement. After the capital increase was completed, the target company, Yiming Kale Biomedical Technology (Shanghai) Co., Ltd., held approximately 68.34%, 15.83%, 6.33%, 6.33%, 6.33% and 3.17% of the shares by the company, Jiaxing Changxin, Biotech, New Territories Chuangyuan, and Mr. Wang, respectively. As a result, the target company remains a non-wholly-owned subsidiary of the company, and its financial results continue to be incorporated into the Group's financial statements.

According to the Zhitong Finance App, Yiming Onko-B (01541.HK) issued an announcement regarding the capital increase of 50 million yuan for its subsidiary Yiming Kale Biomedical Technology (Shanghai). As of the date of this announcement, the capital increase and related industrial and commercial registration procedures have been completed. Investors have paid RMB 50 million in consideration in accordance with the capital increase agreement. After the capital increase was completed, the target company, Yiming Kale Biomedical Technology (Shanghai) Co., Ltd., held approximately 68.34%, 15.83%, 6.33%, 6.33%, 6.33% and 3.17% of the shares by the company, Jiaxing Changxin, Biotech, New Territories Chuangyuan, and Mr. Wang, respectively. As a result, the target company remains a non-wholly-owned subsidiary of the company, and its financial results continue to be incorporated into the Group's financial statements.